Vanda Pharmaceuticals (VNDA) Total Liabilities (2009 - 2026)

Vanda Pharmaceuticals' Total Liabilities history runs 18 years deep, the most recent figure standing at $152.8 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 26.75% year-over-year to $152.8 million; the TTM figure through Mar 2026 stood at $152.8 million (up 26.75% YoY), while the FY2025 annual figure was $161.8 million, up 37.48% from the prior year.
• Total Liabilities came in at $152.8 million for Q1 2026 at Vanda Pharmaceuticals, down from $161.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $161.8 million in Q4 2025 to a low of $98.5 million in Q3 2023.
• A 5-year average of $116.2 million and a median of $108.7 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities decreased 7.19% in 2023 and soared 37.48% in 2025, its largest moves.
• Vanda Pharmaceuticals' Total Liabilities stood at $107.0 million in 2022, then fell by 3.29% to $103.5 million in 2023, then climbed by 13.65% to $117.7 million in 2024, then surged by 37.48% to $161.8 million in 2025, then decreased by 5.56% to $152.8 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $152.8 million, $161.8 million, and $135.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison